![Sanj Patel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sanj Patel
Amministratore Delegato presso KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
Patrimonio netto: 32 M $ in data 31/05/2024
Profilo
Sanj K.
Patel is the founder of the Sarcoma Foundation of America (founded in 2015) and Kiniksa Pharmaceuticals Ltd.
(founded in 2015).
He is currently the Chief Executive Officer & Director at Kiniksa Pharmaceuticals Corp.
and the Chairman & Chief Executive Officer at Kiniksa Pharmaceuticals International Plc.
In the past, he served as the President, Chief Executive Officer & Director at Synageva BioPharma Corp.
(2008-2015), Independent Director at BioCryst Pharmaceuticals, Inc. (2015-2018), Independent Director at Intercept Pharmaceuticals, Inc. (2014-2015), Independent Director at Syros Pharmaceuticals, Inc. (2016-2018), and Head-Global Clinical Research Operations Council at Genzyme Corp.
(1999-2008).
Mr. Patel obtained his undergraduate degree from London South Bank University and his graduate degree from Ealing Hammersmith & West London College.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
15/04/2024 | 1 526 160 ( 37.18% ) | 29 M $ | 31/05/2024 | |
0.43% | 15/04/2024 | 172 837 ( 0.43% ) | 3 M $ | 31/05/2024 |
Posizioni attive di Sanj Patel
Società | Posizione | Inizio |
---|---|---|
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC | Amministratore Delegato | 01/07/2015 |
Sarcoma Foundation of America | Fondatore | 01/01/2015 |
Kiniksa Pharmaceuticals Corp.
![]() Kiniksa Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Part of Kiniksa Pharmaceuticals Ltd., Kiniksa Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company that develops and commercializes therapeutic medicines for patients suffering from debilitating diseases. The company is based in Lexington, MA. The CEO of the company is Sanj K. Patel. | Amministratore Delegato | - |
Precedenti posizioni note di Sanj Patel
Società | Posizione | Fine |
---|---|---|
BIOCRYST PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 20/06/2018 |
SYROS PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 14/06/2018 |
INTERCEPT PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 24/11/2015 |
SYNAGEVA BIOPHARMA CORP | Amministratore Delegato | 22/06/2015 |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/01/2008 |
Formazione di Sanj Patel
London South Bank University | Undergraduate Degree |
Ealing Hammersmith & West London College | Graduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
BIOCRYST PHARMACEUTICALS, INC. | Health Technology |
SYROS PHARMACEUTICALS, INC. | Health Technology |
Aziende private | 5 |
---|---|
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Synageva BioPharma Corp.
![]() Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Sarcoma Foundation of America | Miscellaneous |
Kiniksa Pharmaceuticals Ltd.
![]() Kiniksa Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Kiniksa Pharmaceuticals International Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA. | Health Technology |
Kiniksa Pharmaceuticals Corp.
![]() Kiniksa Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Part of Kiniksa Pharmaceuticals Ltd., Kiniksa Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company that develops and commercializes therapeutic medicines for patients suffering from debilitating diseases. The company is based in Lexington, MA. The CEO of the company is Sanj K. Patel. | Health Technology |
- Borsa valori
- Insiders
- Sanj Patel